---
title: "FENGYUAN PHARMACEUTICAL's controlling shareholder plans to transfer 5.1% of its shares, which will not affect control"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252507532.md"
description: "Anhui FENGYUAN PHARMACEUTICAL's controlling shareholder FENGYUAN Group and its concerted actor Ma'anshan FENGYUAN intend to transfer 23,698,554 shares, accounting for 5.10% of the total share capital, to Hainan Guihe Dayi, at a transfer price of 6.72 yuan/share, totaling 159 million yuan. This transaction does not affect the company's control and does not involve a tender offer or related party transactions, but it requires compliance review by the Shenzhen Stock Exchange, and the final completion is uncertain"
datetime: "2025-08-11T12:57:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252507532.md)
  - [en](https://longbridge.com/en/news/252507532.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252507532.md)
---

# FENGYUAN PHARMACEUTICAL's controlling shareholder plans to transfer 5.1% of its shares, which will not affect control

On August 11, 2025, Anhui FENGYUAN PHARMACEUTICAL Co., Ltd. announced that its controlling shareholder FENGYUAN Group and its concerted party Ma'anshan FENGYUAN intend to transfer 23,698,554 shares of the company, accounting for 5.10% of the total share capital, to Hainan Guihe Dayi at a transfer price of 6.72 yuan per share, totaling 159 million yuan. The funds for the transferee are self-owned, and they promise not to reduce their holdings within 18 months after the transfer. This transaction does not involve a tender offer, related party transactions, will not lead to a change in the company's control, and will not affect the company's governance and operations. However, the transaction is subject to compliance review by the Shenzhen Stock Exchange, and there is uncertainty regarding its final completion

### Related Stocks

- [000153.CN](https://longbridge.com/en/quote/000153.CN.md)

## Related News & Research

- [CSPC Innovation Pharmaceutical: Biopharma licensing and product launches drove record revenue and profit growth](https://longbridge.com/en/news/296129143.md)
- [SandboxAQ introduces AQPotency for virtual drug screening](https://longbridge.com/en/news/296467103.md)
- [Curql invests in pet healthcare platform Wagmo](https://longbridge.com/en/news/296396050.md)
- [09:02 ETEvolved By Nature's Peptide Platform Used in FDA-Cleared Prescription Therapy for the Management of Atopic Dermatitis](https://longbridge.com/en/news/296496101.md)
- [13:22 ET/C O R R E C T I O N -- Rayence/](https://longbridge.com/en/news/296256530.md)